Amir Muhaimin Akmal Shukri

Amir Muhaimin Akmal Shukri

Auto-generated profile, based on publicly available information

Amir Muhaimin Akmal Shukri

Institute of Medical Molecular Biotechnology (IMMB), Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Malaysia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2022 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
ASAmir Muhaimin Akmal Shukri
Amir Muhaimin Akmal Shukri
SWSeok Mui Wang
Seok Mui Wang
SCSuet Lin Chia
Suet Lin Chia
SNSiti Farah Alwani Mohd Nawi
Siti Farah Alwani Mohd Nawi
Since the first detection of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus remains a public health concern. Several public health measures have been implemented in an effort to curb the infections. However, the effectiveness of these strategies was threatened with the emergence of numerous SARS-CoV-2 variants in all parts of the globe, due to the persistent mutations as part of the viral evolution. Mutations that usually occur in its spike glycoprotein, allow SARS-CoV-2 to possess advantageous characteristics for its survivability and persistence. This has led to poor performance of diagnostic kits which have caused non-specific and insensitive detection of these variants, resulting in undetermined infection. The variants also have caused the increased severity of COVID-19, involving hospitalisation rates, ICU admissions, and deaths. Many have reported the vaccine-breakthrough infections and reduced effectiveness of vaccination, which is supposed to provide an effective degree of protection against COVID-19 infections. Due to these issues, this review summarises the impacts related to SARS-CoV-2 variants emergence towards the performance of diagnostic kits, transmissibility of the virus, severity of disease, and effectiveness of COVID-19 vaccines.

2 September 2024 in The Analyst
Verified
Journal Article
Closed access
PDF file
ASAmir Muhaimin Akmal Shukri
Amir Muhaimin Akmal Shukri
SWSeok Mui Wang
Seok Mui Wang
CFChaoli Feng
Chaoli Feng
SCSuet Lin Chia
Suet Lin Chia
SNSiti Farah Alwani Mohd Nawi
Siti Farah Alwani Mohd Nawi
MCMarimuthu Citartan
Marimuthu Citartan
A myrid of aptamers were isolated thus far against SARS-CoV-2 by using in silico selection.

29 August 2025 in Virology Journal
Verified
Journal Article
Open access
PDF file
NMNur Aida Laili Mislan
Nur Aida Laili Mislan
MCMarimuthu Citartan
Marimuthu Citartan
ASAmir Muhaimin Akmal Shukri
Amir Muhaimin Akmal Shukri
JSJeyanthi Suppiah
Jeyanthi Suppiah
RZRozainanee Mohd Zain
Rozainanee Mohd Zain
SWSeok Mui Wang
Seok Mui Wang
Dengue virus (DENV) poses a significant global health burden, with current treatments being limited and primarily supportive. Aptamers are an emerging class of molecular recognition elements that are cheaper, less immunogenic and have no batch-to-batch variation as compared to antibodies. In light of their advantages, aptamers can potentially offer a novel approach to counteract DENV by targeting viral proteins or host factors essential for viral replication and pathogenesis. This review gleans the recent advancements in the development of aptamer-based therapeutic agents targeting dengue virus infection. The latest advancement on aptamers targeting specific dengue virus components such as capsid protein (C), envelope domain III (E3), and nonstructural proteins (NS); and their roles in inhibiting viral replication are highlighted. Although the development of aptamers as potential therapeutics for dengue infections is still in its early stages, based on their therapeutic potentiality, they hold immense potential for dengue viral treatment.

5 May 2026 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
AMAkmal Shukri Amir Muhaimin
Akmal Shukri Amir Muhaimin
MIMuhammad Amin Ibrahim
Muhammad Amin Ibrahim
MRMohammed Fauzi Abdul Rani
Mohammed Fauzi Abdul Rani
MMMariam Mohamad
Mariam Mohamad
SWSeok Mui Wang
Seok Mui Wang
SNSiti Farah Alwani Mohd Nawi
Siti Farah Alwani Mohd Nawi
The dynamics and protectiveness of the hybrid immune responses, especially in individuals who have experienced severe COVID-19, remain to be fully understood. This study aims to identify the prevalence and persistence of neutralising antibodies throughout time, and to investigate the longitudinal profile of anti-SARS-CoV-2 IgG antibodies targeting the receptor binding domain (RBD) in patients recovering from severe COVID-19. A total of 42 hospitalised COVID-19 survivors were enrolled from three medical centres in Malaysia. Serial blood samples were collected at four time points post-discharge (approximately 90, 180, 270 and 360 days). IgG titres were quantified using ELISA and neutralising antibodies (NAbs). Statistical analyses were performed to explore antibody dynamics and correlations. Among 42 participants, 24 completed all four visits. Mean antibody titre showed an initial decline after the first visit, followed by a gradual increase over time, with the highest being at Visit 4 (360-390 days post-discharge). The highest titre (266.7 ± 30.9 BAU/mL) was observed in a recipient, 10 days after receiving the fourth vaccination. All participants except one demonstrated protective NAbs at the final visit. Higher BMI was significantly associated with disease severity (P = 0.006), while IgG titres were higher in individuals with more severe initial infections (Category 5). This study highlights the persistence of antibody response with hybrid immunity, with the booster vaccinations contributing to increased antibody titres. RBD-specific IgG titres provide useful insights into their trends, while the concurrent NAbs assessment is important for a comprehensive understanding of the protective efficacy following hybrid immunity.